Synthesis of 17β-estradiol platinum(II) complexes: Biological evaluation on breast cancer cell lines

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 22, 2003, Pages 3927-3931

  Descôteaux, Caroline ^a   Provencher Mandeville, Josée ^a   Mathieu, Isabelle ^a   Perron, Valérie ^a   Mandal, Sanat K ^b   Asselin, Éric ^a   Bérubé, Gervais ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^b GIS Applications Specialist   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEDAPLATIN; OXALIPLATIN; PLATINUM COMPLEX; PYRIDINE DERIVATIVE; 17BETA ESTRADIOL PLATINUM(II); 17BETA-ESTRADIOL PLATINUM(II); ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ESTRADIOL;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; EVALUATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; BREAST TUMOR; CELL SURVIVAL; CHEMISTRY; CONFORMATION; DRUG EFFECT; FEMALE; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; ESTRADIOL; FEMALE; HUMANS; MOLECULAR CONFORMATION; ORGANOPLATINUM COMPOUNDS;

EID: 0242285616     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.011     Document Type: Article

References (20)

1. Wong E., Giandomenico C.M. Chem. Rev. 99:1999;2451.
2. (a) Jamieson E.R., Lippard S.J. Chem. Rev. 99:1999;2467
3. (b) Scozzafava A., Casini A., Supuran C.T. Curr. Med. Chem. 9:2002;1167
4. (c) Casini A., Scozzafava A., Supuran C.T. Environm. Health Persp. 110:2002;801.
5. (a) Reedijk J. Inorg. Chim. Acta. 198:1992;873
6. (b) Lemaire D., Fouchet M.-H., Kozelka J. J. Inorg. Biochem. 53:1994;261
7. (c) Hydes P.C., Russell M.J.H. Cancer Metastasis Rev. 7:1988;67.
8. Greene, T. W.; Wuts, P. G. M. In Protective Groups in Organic Synthesis, 3rd ed.; John Wiley & Sons: New York, 1999.
9. Ruest L., Blouin G., Deslongchamps P. Synth. Commun. 6:1976;169.
10. Tremblay R., Auger S., Poirier D. Synth. Commun. 25:1995;2483.
11. Dionne P., Ngatcha B.T., Poirier D. Steroid. 62:1997;674.
12. (a) Séné A., Bérubé G.C., Gaudreault R. Drug Des. Discov. 15:1998;277
13. (b) He Y., Groleau S.C., Gaudreault R., Caron M., Thérien H.-M., Bérubé G. Bioorg. Med. Chem. Lett. 19:1995;2217
14. (c) Bérubé G., Wheeler P., Ford C.H.J., Gallant M., Tsaltas Z. Can. J. Chem. 71:1993;1327.
15. Al-Allaf T., Castan P., Turpin R., Wimmer S. C. R. Acad. Sci. 314:1992;1029.
16. 6): δ 155.9, 138.4, 132.1, 126.9, 116.0, 113.6, 90.6, 67.1, 48.5, 47.6, 45.8, 44.8, 40.2, 39.2, 38.9, 34.8, 34.6, 33.7, 30.5, 28.9, 28.3, 27.2, 25.1, 12.5 (18-C).
17. Carmichael J., DeGrapp W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Cancer Res. 47:1987;943.
18. Ford C.H.J., Richardson V.J., Tsaltas G. Cancer Chemother. Pharmacol. 24:1989;295.
19. Horwitz K.B., Zava D.T., Thilagar A.K., Jensen E.M., McGuire W.L. Cancer Res. 38:1978;2434.
20. BioMedCAChe 6.0; Fujitsu Limited: USA, 2003.